Blood Proteome Profiling Identifies Biomarkers in Ischemic Stroke

NCT ID: NCT06729385

Last Updated: 2025-02-21

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-12-01
• Study Completion Date: 2025-02-20

Brief Summary

Endovascular thrombectomy and intravenous thrombolysis have become key therapeutic approaches for acute ischemic stroke. However, due to time window limitations, many patients are unable to receive reperfusion therapy, and the majority only receive supportive treatment. Ischemic stroke-related complications, including edema and infection, gradually subside after 7 days post-stroke, with the patient's condition generally stabilizing. Endogenous repair mechanisms will play a critical role in the coming months. This study aims to predict prognostic biomarkers for ischemic stroke patients who have not undergone reperfusion therapy, using blood proteomics data. All samples in our study are derived from this experiment. Our goal is to elucidate the molecular mechanisms underlying post-reperfusion prognosis and to provide insights for optimizing stroke treatment strategies.

Conditions

Stroke

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Obvious group

Patients with large artery atherosclerotic ischemic stroke, presenting 7 to 30 days after onset, and who have not received reperfusion therapy.

The blood Proteome Profiling

Intervention Type: DIAGNOSTIC_TEST

Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.

Interventions

The blood Proteome Profiling

Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Age ≥18.
• Clinical signs consistent with acute ischemic stroke (TOAST classification: large artery atherosclerosis)
• 7 to 30 days from symptom onset.

Exclusion Criteria

• Severe infection or multiple organ failure.
• Untreated moderate or severe coronary artery stenosis, or a history of coronary artery bypass surgery.
• Ongoing hemodialysis or peritoneal dialysis, or severe renal insufficiency characterized by a glomerular filtration rate (GFR) of less than 30 ml/min or serum creatinine levels exceeding 220 mmol/L (2.5 mg/dl).
• Known intracranial aneurysm or cerebral arteriovenous malformation.
• Malignant brain tumor or central nervous system (CNS) infection.
• Pre-existing neurological or psychiatric conditions that could confound the neurological or functional assessments.
• Baseline platelet count <50 × 109/L.
• Pregnancy or lactation at the time of admission.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Capital Medical University

OTHER

Sponsor Role: lead

Responsible Party

Ji Xunming,MD,PhD

MD.PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Xuanwu Hospital

Beijing, Beijing Municipality, China

People's hospital of Xiushan Country

Chongqing, Chongqing Municipality, China

Nanyang Nanshi Hospital

Nanyang, Henan, China

Liuyang Jili Hospital, Hunan, China

Changsha, Hunan, China

Countries

China

Other Identifiers

PBIS

Identifier Type: -

Identifier Source: org_study_id